Stock NOVA NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Novo Nordisk A/S Deutsche Boerse AG

Equities

NOVA

US6701002056

Real-time Estimate Tradegate
Other stock markets
 01:44:42 05/07/2024 pm IST 		5-day change 1st Jan Change
130.8 EUR +1.36% Intraday chart for Novo Nordisk A/S -2.62% +39.78%
04/07 ETF of the week: Investing in strong trends with the momentum theme Our Logo
04/07 NOVO NORDISK : Deutsche Bank remains its Buy rating ZD

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.93 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.78% 624B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.07% 809B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.05% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.44% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.72% 289B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.62% 240B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+0.61% 219B
A+
NOVARTIS AG Stock Novartis AG
+14.56% 220B
B-
AMGEN INC. Stock Amgen Inc.
+7.42% 166B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. NOVA Stock
  5. Ratings Novo Nordisk A/S